Reselute is proud to announce that the company has been awarded a National Institutes of Health (NIH) FastTrack SBIR combined Phase I/II grant. This significant milestone provides nondilutive funding that will accelerate the company’s research and development efforts focused on addressing complex orthopedic infections.
The funding will support continued development of the Reselution Intramedullary System, Reselute’s innovative platform designed to deliver targeted infection treatment while supporting structural stability within the bone. By expanding research into additional clinical indications, the company aims to broaden the impact of its technology for patients facing challenging orthopedic infections.
Receiving this NIH FastTrack SBIR award highlights the promise of Reselute’s approach and reinforces the importance of advancing new solutions for orthopedic infection care. With this support, the Reselute team will continue progressing toward technologies that improve treatment outcomes and expand options for surgeons and patients alike.
